PEPN1812 - A Phase 1 Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia
Study of Flotetuzumab for Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Sponsor: Children's Oncology Group
Enrolling: Male and Female Patients
IRB Number: AAAS8739
U.S. Govt. ID: NCT04158739
Contact: Luca Szalontay: 212-305-9770 / ls3399@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find the highest dose of Flotetuzumab that can be given safely to patients who have a certain type of leukemia called Acute Myeloid Leukemia (AML) that has relapsed (has come back after treatment) or is refractory (never responded to treatment). Flotetuzumab is an experimental treatment that works by targeting certain proteins on the outside of leukemia cells and using the patient's own immune system to kill the leukemia cells.
This study is closed
Investigator
Luca Szalontay, MD
Do You Qualify?
Is your child under the age of 21? Yes No
Does your child have relapsed/refractory Acute Myeloid Leukemia (AML)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Luca Szalontay
ls3399@cumc.columbia.edu
212-305-9770